Wednesday, November 18, 2026
FDA GUIDANCENovember 06, 2026

FDA Grants Premarket Approval (PMA P130021): Evolut™ FX Delivery Catheter System of the Evolut™ FX Transcatheter Aortic Valve System; Evolut™ FX+ Transcatheter Aorti by Medtronic, Inc.

Affected Product:Evolut™ FX Delivery Catheter System of the Evolut™ FX Transcatheter Aortic Valve System; Evolut™ FX+ Transcatheter Aorti
Recalling Firm / Manufacturer:Medtronic, Inc.
Reference / Recall Number:P130021
Executive Summary:

FDA awards Class III Premarket Approval (PMA P130021) for Evolut™ FX Delivery Catheter System of the Evolut™ FX Transcatheter Aortic Valve System; Evolut™ FX+ Transcatheter Aorti sponsored by Medtronic, Inc..

The FDA Center for Devices and Radiological Health has granted Premarket Approval (PMA) for Evolut™ FX Delivery Catheter System of the Evolut™ FX Transcatheter Aortic Valve System; Evolut™ FX+ Transcatheter Aorti, classified as a Class III life-supporting or life-sustaining medical device.

PMA Approval Dossier

  • PMA Number: P130021
  • Applicant: Medtronic, Inc.
  • Device Designation: Evolut™ FX Delivery Catheter System of the Evolut™ FX Transcatheter Aortic Valve System; Evolut™ FX+ Transcatheter Aorti
  • Product Code: NPT
  • Decision Code: OK30

Approval was based on rigorous review of valid scientific evidence, including bench testing, animal studies, and human clinical trial outcomes establishing a reasonable assurance of safety and effectiveness.

Official Regulatory Docket:Open Agency Docket